Science Explorer Interactive view Map
Company · Durham · United States

G1 Therapeutics (United States)

g1therapeutics.comROR OpenAlex
Research works
81
▲ 90% vs 2013–17
Citations
1.8k
22.1 per fractional work
Top-10% rate
13.8%
record average 16.5%
Open access
47%
world 28%

Not ranked overall: G1 Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.03× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 3.19× its world share, 4 worksBiochemistry, Geneti…Immunology and Microbiology: 5.40× its world share, 1 worksImmunology and Micro…Neuroscience: 0.29× its world share, 0 worksNeuroscienceChemistry: 1.35× its world share, 1 worksChemistryEngineering: 0.03× its world share, 0 worksEngineeringEnvironmental Science: 0.56× its world share, 1 worksEnvironmental ScienceMaterials Science: 0.08× its world share, 0 worksMaterials ScienceMathematics: 0.36× its world share, 0 worksMathematicsHealth Professions: 0.21× its world share, 0 worksHealth ProfessionsMedicine: 3.62× its world share, 18 worksMedicineEconomics, Econometrics and Finance: 0.37× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 5.4×. Every wedge is a field page.

Who are the top researchers at G1 Therapeutics (United States)?

Ranked on the composite score, Jay C. Strum and Jessica A. Sorrentino lead among researchers whose main affiliation is G1 Therapeutics (United States).

  1. 1 Jay C. Strum United States · #617,936 worldwide 66 citations · 17 works
  2. 2 Jessica A. Sorrentino United States · #1,167,821 worldwide 19 citations · 19 works
All ranked researchers at G1 Therapeutics (United States)

Which keywords describe research at G1 Therapeutics (United States)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Immunotherapy, Targeted Therapy, Prognostic Factors, Tumor Microenvironment, Clinical Trials, Cancer and Metastatic Breast Cancer.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 25 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 25 words, with their numbers
  1. Chemotherapy4▲ 22×10 topics
  2. Immunotherapy3▲ 17×7 topics
  3. Prognostic Factors3▲ 22×4 topics
  4. Targeted Therapy3▲ 44×4 topics
  5. Cancer2▲ 7.0×9 topics
  6. Clinical Trials2▲ 14×4 topics
  7. Tumor Microenvironment2▲ 22×7 topics
  8. Metastasis2▲ 25×4 topics
  9. Metastatic Breast Cancer2▲ 153×2 topics
  10. Genomic Profiles2▲ 178×1 topic
  11. Small-Cell Lung Cancer2▲ 178×1 topic
  12. Breast Cancer2▲ 30×2 topics
  13. CDK4/6 Inhibitors2▲ 250×1 topic
  14. Inflammation2▲ 3.0×15 topics
  15. Palbociclib2▲ 250×1 topic
  16. Molecular Characterization2▲ 31×4 topics
  17. Immune Checkpoint Blockade1▲ 45×1 topic
  18. PD-1 and PD-L11▲ 45×1 topic
  19. Antimicrobial Agents1▲ 270×1 topic
  20. Cancer Risk1▲ 19×2 topics
  21. Febrile Neutropenia1▲ 270×1 topic
  22. Genetic Testing1▲ 36×2 topics
  23. Quality of Life1▲ 2.8×7 topics
  24. Hereditary Syndromes1▲ 123×1 topic
  25. Microsatellite Instability1▲ 123×1 topic

Which research topics does G1 Therapeutics (United States) publish most on?

By volume in 2022–2025: Lung Cancer Research Studies, Advanced Breast Cancer Therapies, Cancer Immunotherapy and Biomarkers and Neutropenia and Cancer Infections.

Lung Cancer Research Stu…2Lung Cancer Research Studies: 2 fractional worksAdvanced Breast Cancer Therapies: 2 fractional worksCancer Immunotherapy and Biomarkers: 1 fractional worksNeutropenia and Cancer Infections: 1 fractional worksGenetic factors in colorectal cancer: 1 fractional worksCancer Treatment and Pha…1Cancer Treatment and Pharmacology: 1 fractional worksVascular Anomalies and Treatments: 0 fractional worksOtitis Media and Relapsing Polychondritis: 0 fractional worksChemokine receptors and signaling: 0 fractional worksImmune Cell Function and Interaction: 0 fractional works
OncologyPulmonary and Respiratory MedicinePathology and Forensic MedicineGenetics2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Lung Cancer Research Studies Oncology 2 works
  2. 2 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 2 works
  3. 3 Cancer Immunotherapy and Biomarkers Oncology 1 works
  4. 4 Neutropenia and Cancer Infections Oncology 1 works
  5. 5 Genetic factors in colorectal cancer Pathology and Forensic Medicine 1 works
  6. 6 Cancer Treatment and Pharmacology Oncology 1 works
  7. 7 Vascular Anomalies and Treatments Genetics 0 works
  8. 8 Otitis Media and Relapsing Polychondritis Rheumatology 0 works
  9. 9 Chemokine receptors and signaling Oncology 0 works
  10. 10 Immune Cell Function and Interaction Immunology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available47.1%not open52.9%

World: 28% of research is openly available.

with international co-authors31.0%domestic only69.0%

World: 19% is written across borders.

How has G1 Therapeutics (United States)'s research output changed?

Output in 2018–2022 was 90% higher than in 2013–2017.

200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Durham

All research institutions in Durham

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.